Shanghai Fengxian District Central Hospital
Shanghai, 201499, China
NCT Number: NCT05182788
To assess the efficacy evaluation of CHOLESWISE Pressed Candy on cardiovascular disease risk factors
Looking for future studies?
Notify Me30 year and older
All sexes
Interventional
Not applicable
Shanghai, 201499, China
This is a single center, randomized, double-blind and placebo controlled study. Subjects are informed to consume the samples every day for 8 weeks.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
consume 2 tablets per day for 8 weeks
consume 2 tablets per day for 8 weeks
Other names: Natto combined Phyllanthus emblica pressed candy
Time frame: Days 1, 28, and 56
Blood pressure will be measured at the beginning, 4-week, and 8-week time points.
Time frame: Days 1, 28, and 56
Blood lipid will be measured at the beginning, 4-week, and 8-week time points.
Time frame: Days 1, 28, and 56
Blood coagulation factor will be measured at the beginning, 4-week, and 8-week time points.
Time frame: Days 1 and 56
Arteriosclerosis will be measured by B-scan ultrasonography at the beginning and 8-week time points.
Time frame: Days 1, 28, and 56
Blood glucose will be measured at the beginning, 4-week, and 8-week time points.
Time frame: Days 1 and 56
Blood hs-CRP will be measured at the beginning 8-week time points.
TCI Co., Ltd.
Industry
The Efficacy Evaluation of CHOLESWISE Pressed Candy on Cardiovascular Health, a Single Center, Randomized, Doubld-Blind, Placebo Controlled Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03188705
Arterial Occlusive Diseases, Arteriosclerosis
Lancaster, Pennsylvania, United States
View Trial DetailsNCT05882045
Body Weight, Cardiovascular Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT02439775
Cardiovascular Diseases, Hypertension
Huntsville, Alabama, United States
View Trial DetailsNCT05820295
Arrhythmias, Cardiac, Atrial Fibrillation
New York, United States
View Trial Details